Treatment with the low molecular weight heparin, enoxaparin sodium ['Lovenox'], in combination with the glycoprotein IIb/IIIa antagonist, eptifibatide ['Integrilin'], improves outcomes in patients with unstable angina pectoris or non-ST segment elevation myocardial infarction (MI), according to preliminary results from the INTERACT*study presented at the 51st Annual Scientific Sessions of the American College of Cardiology (ACC) [Atlanta, US; March 2002].1,2Significant reductions in the incidences of death or MI within 30 days of treatment, and the occurrences of major bleeding events and ischaemia, were achieved in patients treated with enoxaparin sodium plus eptifibatide, compared with those given the current standard therapy of unfractionated heparin plus eptifibatide.'Previous studies have established that drugs such as eptifibatide added to traditional therapies, including aspirin and unfractionated heparin, help reduce the unacceptably high incidence of adverse outcomes associated with unstable angina and non-ST-segment elevation myocardial infarction',said the study's principal investigator, Dr Shaun Goodman from the University of Toronto, Canada.'Our study shows that by replacing unfractionated heparin with the low molecular weight heparin,[enoxaparin sodium],outcomes can be further improved'.